Cdc2 Inhibitors
Items 11 to 20 of 40 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a potent inhibitor of Cdc2, distinguished by its capacity to disrupt the enzyme's interaction with cyclins. This compound engages in specific hydrogen bonding and hydrophobic interactions, which stabilize a non-productive enzyme-substrate complex. Its unique structural features facilitate selective binding, resulting in altered reaction kinetics that favor a competitive inhibition model. This modulation of Cdc2 activity impacts cell cycle progression, showcasing its intricate role in cellular regulation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime acts as a selective inhibitor of Cdc2, characterized by its ability to interfere with the enzyme's phosphorylation state. This compound exhibits unique interactions with the ATP-binding site, leading to conformational changes that hinder substrate access. Its distinct molecular architecture promotes a strong affinity for Cdc2, resulting in altered enzymatic kinetics and a shift in the balance of cell cycle regulatory mechanisms, highlighting its role in cellular dynamics. | ||||||
NU 6140 | 444723-13-1 | sc-202531 | 5 mg | $147.00 | 1 | |
NU 6140 functions as a potent Cdc2 inhibitor, distinguished by its ability to disrupt the enzyme's catalytic activity through specific binding interactions. This compound engages with critical residues within the active site, inducing steric hindrance that impedes substrate binding. Its unique structural features facilitate selective modulation of Cdc2's regulatory pathways, ultimately affecting cell cycle progression and checkpoint control, showcasing its intricate role in cellular regulation. | ||||||
5-Iodo-indirubin-3′-monoxime | 331467-03-9 | sc-221030 | 1 mg | $82.00 | ||
5-Iodo-indirubin-3'-monoxime acts as a selective inhibitor of Cdc2, characterized by its unique ability to alter enzyme conformation through targeted interactions. This compound stabilizes a non-productive enzyme-substrate complex, effectively slowing reaction kinetics. Its distinct molecular architecture allows for precise engagement with key amino acid residues, influencing phosphorylation events and modulating downstream signaling pathways, thereby impacting cellular dynamics and regulatory mechanisms. | ||||||
Cdk/CKI Inhibitor, (R)-DRF053 | sc-221408 | 5 mg | $209.00 | 2 | ||
(R)-DRF053 is a potent Cdk/CKI inhibitor that selectively targets Cdc2, showcasing a unique mechanism of action through its ability to disrupt cyclin-dependent kinase activity. This compound engages in specific hydrogen bonding and hydrophobic interactions with the enzyme's active site, leading to a conformational shift that impedes substrate access. Its kinetic profile reveals a competitive inhibition pattern, effectively modulating cell cycle progression and influencing regulatory networks within the cell. | ||||||
Indirubin Derivative E804 | 854171-35-0 | sc-221751 | 1 mg | $204.00 | 1 | |
Indirubin Derivative E804 is a selective inhibitor of Cdc2, characterized by its unique ability to stabilize the inactive conformation of the kinase. This compound exhibits strong π-π stacking interactions with aromatic residues in the active site, which alters the enzyme's dynamics. Its binding affinity is influenced by specific electrostatic interactions, resulting in a distinct allosteric modulation of kinase activity. The compound's kinetic behavior suggests a non-competitive inhibition mechanism, impacting cellular signaling pathways. | ||||||
Indirubin-5-sulfonic acid sodium salt | sc-221755 sc-221755A | 1 mg 5 mg | $57.00 $324.00 | |||
Indirubin-5-sulfonic acid sodium salt acts as a potent Cdc2 inhibitor, distinguished by its capacity to disrupt the enzyme's phosphorylation state. It engages in hydrogen bonding with key amino acid residues, leading to conformational changes that hinder substrate access. The compound's unique sulfonic acid group enhances solubility and facilitates interactions with the enzyme's active site, promoting a shift in reaction kinetics that alters cell cycle regulation. Its influence on protein dynamics underscores its role in modulating kinase activity. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I functions as a Cdc2 inhibitor by selectively binding to the enzyme's active site, inducing steric hindrance that impedes substrate binding. Its cyclic structure allows for unique interactions with the enzyme, stabilizing a non-productive conformation. The compound's ability to form transient complexes with Cdc2 alters the enzyme's catalytic efficiency, impacting downstream signaling pathways. This modulation of enzyme dynamics highlights its role in cell cycle control. | ||||||
CR8, (R)-Isomer | 294646-77-8 | sc-311306 | 5 mg | $174.00 | ||
CR8, (R)-Isomer acts as a Cdc2 modulator through its unique stereochemistry, which enhances its affinity for the enzyme's regulatory sites. This compound engages in specific hydrogen bonding and hydrophobic interactions, leading to conformational changes that disrupt the enzyme's normal activity. By influencing the phosphorylation state of key substrates, CR8 alters the kinetics of cell cycle progression, showcasing its intricate role in cellular regulation. | ||||||
TAK 165 | 366017-09-6 | sc-361372 sc-361372A | 10 mg 50 mg | $139.00 $781.00 | ||
TAK 165 functions as a Cdc2 modulator by selectively binding to the enzyme's active site, promoting unique conformational shifts that affect its catalytic efficiency. This compound exhibits distinct electrostatic interactions and van der Waals forces, which stabilize its complex with Cdc2. By modulating the phosphorylation dynamics of cyclins, TAK 165 intricately influences cell cycle checkpoints, highlighting its role in the regulation of cellular proliferation. | ||||||